Home / Health / Cerus Blood Tech Shows Promise in Transfusions
Cerus Blood Tech Shows Promise in Transfusions
3 Nov
Summary
- Cerus' technology treats red blood cells for transfusions.
- Late-stage study shows treated cells perform like normal ones.
- The technology aims to reduce pathogen risks in donated blood.
Cerus Corp has reported promising outcomes from a late-stage clinical study concerning its blood-safety technology. The Intercept technology is specifically engineered to mitigate the risks associated with viruses, bacteria, and other pathogens found in donated blood products.
The study demonstrated that red blood cells treated with Cerus' Intercept system performed equally well when compared to conventionally treated red blood cells in patients who received transfusions.
This finding is a critical development for transfusion medicine, suggesting a potential to enhance the safety profile of blood transfusions while maintaining efficacy.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
